Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 Apr 7;95:68-74. doi: 10.1016/j.ejca.2018.03.002. [Epub ahead of print]

PMID:
29635146
2.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

3.

Development and validation of a duplex real-time PCR assay for the diagnosis of equine piroplasmosis.

Lobanov VA, Peckle M, Massard CL, Brad Scandrett W, Gajadhar AA.

Parasit Vectors. 2018 Mar 2;11(1):125. doi: 10.1186/s13071-018-2751-6.

4.

Durvalumab in urothelial cancers.

Lavaud P, Hamilou Z, Loriot Y, Massard C.

Expert Rev Anticancer Ther. 2018 Apr;18(4):311-318. doi: 10.1080/14737140.2018.1443812. Epub 2018 Mar 5.

PMID:
29486607
5.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

PMID:
29454743
6.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
7.

Comparison of heat shock protein 70 kDa and 18S rDNA genes for molecular detection and phylogenetic analysis of Babesia vogeli from whole blood of naturally infected dogs.

Paulino PG, Pires MS, Silva CBD, Peckle M, Costa RLD, Vitari GLV, Abreu APM, Almosny NRP, Massard CL, Santos HA.

Ticks Tick Borne Dis. 2018 Mar;9(3):556-562. doi: 10.1016/j.ttbdis.2018.01.013. Epub 2018 Feb 1.

PMID:
29409719
8.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.

PMID:
29331748
9.

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

Louvel G, Bahleda R, Ammari S, Le Péchoux C, Levy A, Massard C, Le Pavec J, Champiat S, Deutsch E.

Eur Respir J. 2018 Jan 4;51(1). pii: 1701737. doi: 10.1183/13993003.01737-2017. Print 2018 Jan. No abstract available.

PMID:
29301923
10.

[Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma].

Bernard-Tessier A, Bonnet C, Lavaud P, Gizzi M, Loriot Y, Massard C.

Bull Cancer. 2018 Feb;105(2):140-145. doi: 10.1016/j.bulcan.2017.10.030. Epub 2017 Dec 28. Review. French.

PMID:
29290331
11.

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO.

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006. Review. French.

PMID:
29269176
12.

Molecular characterization of Theileria equi in horses from the state of Rio de Janeiro, Brazil.

Peckle M, Pires MS, Silva CBD, Costa RLD, Vitari GLV, Senra MVX, Dias RJP, Santos HA, Massard CL.

Ticks Tick Borne Dis. 2018 Feb;9(2):349-353. doi: 10.1016/j.ttbdis.2017.11.011. Epub 2017 Nov 28.

PMID:
29223587
13.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.

Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin MP, Alt M, Bahleda R, Varga A, Boetsch C, Franjkovic I, Heil F, Lahr A, Lechner K, Morel A, Nayak T, Rossomanno S, Smart K, Stubenrauch K, Krieter O.

Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. doi: 10.1158/1078-0432.CCR-17-1588. Epub 2017 Dec 7.

PMID:
29217526
14.

A polymorphous bullous dermatosis.

Drahy F, Hotz C, Ortonne N, Ghoufi L, Grootenboer-Mignot S, Massard C, Perrin MP, Chosidow O, Ingen-Housz-Oro S.

Lancet Oncol. 2017 Dec;18(12):e776. doi: 10.1016/S1470-2045(17)30461-8. No abstract available.

PMID:
29208443
15.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2017 Dec;87:122-130. doi: 10.1016/j.ejca.2017.10.013. Epub 2017 Nov 14. Erratum in: Eur J Cancer. 2018 Feb 14;:.

PMID:
29145038
16.

[Focus on DNA - repair].

Massard C.

Bull Cancer. 2017 Nov;104(11):956-957. doi: 10.1016/j.bulcan.2017.10.002. Epub 2017 Nov 11. French. No abstract available.

PMID:
29132680
17.

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC.

Invest New Drugs. 2017 Nov 2. doi: 10.1007/s10637-017-0531-3. [Epub ahead of print]

PMID:
29094232
18.

Molecular and Morphological Characterization of a Brazilian Lineage of Plasmodium ( Novyella) Unalis in Turdus Spp. (Passeriformes) of the Atlantic Forest, with Remarks on New Hosts and High Genetic Variation.

Tostes R, Dias RJP, de Oliveira L, Senra MVX, Massard CL, D'Agosto M.

J Parasitol. 2018 Feb;104(1):70-78. doi: 10.1645/16-189. Epub 2017 Nov 8.

PMID:
28930498
19.

Are phase I trials safe for older patients?

Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A.

J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. Review.

PMID:
28890328
20.

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Guida A, Albiges L, Derosa L, Loriot Y, Massard C, Fizazi K, Escudier B.

Clin Genitourin Cancer. 2017 Dec;15(6):e1081-e1088. doi: 10.1016/j.clgc.2017.07.015. Epub 2017 Aug 12.

PMID:
28888866
21.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Menis J, Gazzah A, Michot JM, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2017 Oct;84:212-218. doi: 10.1016/j.ejca.2017.07.027. Epub 2017 Aug 18.

PMID:
28826074
22.

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C.

Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18.

PMID:
28826073
23.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

PMID:
28817753
24.

[The breakthrough of personalized medicine, new hopes and new challenges].

Flippot R, Massard C, Auclin E, Azria D, Bourien H, Rochigneux P, Schernberg A, Verlingue L, Zafrani L, Vignot S.

Bull Cancer. 2017 Sep;104(9):735-743. doi: 10.1016/j.bulcan.2017.07.003. Epub 2017 Aug 12. Review. French.

PMID:
28807365
25.

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence.

Dercle L, Ammari S, Bateson M, Durand PB, Haspinger E, Massard C, Jaudet C, Varga A, Deutsch E, Soria JC, Ferté C.

Sci Rep. 2017 Aug 11;7(1):7952. doi: 10.1038/s41598-017-08310-5.

26.

Patient-reported tolerability of adverse events in phase 1 trials.

Henon C, Lissa D, Paoletti X, Thibault C, Le Tourneau C, Lanoy E, Hollebecque A, Massard C, Soria JC, Postel-Vinay S.

ESMO Open. 2017 Jun 23;2(2):e000148. doi: 10.1136/esmoopen-2016-000148. eCollection 2017.

27.

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.

Eur Urol Focus. 2017 Mar 7. pii: S2405-4569(17)30065-2. doi: 10.1016/j.euf.2017.02.017. [Epub ahead of print] Review.

PMID:
28753865
28.

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.

Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K.

Eur Urol Focus. 2017 Feb 14. pii: S2405-4569(17)30024-X. doi: 10.1016/j.euf.2017.01.015. [Epub ahead of print]

29.

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M.

Eur Urol Focus. 2017 Feb 27. pii: S2405-4569(17)30019-6. doi: 10.1016/j.euf.2017.01.010. [Epub ahead of print]

30.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
31.

Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.

Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M, Wollmer P, Trägårdh E, Bondesson E, Edenbrandt L, Fizazi K, Bjartell A.

Eur Urol Focus. 2016 Dec;2(5):547-552. doi: 10.1016/j.euf.2016.01.005. Epub 2016 Feb 3.

32.

Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey.

Bultijnck R, Surcel C, Ploussard G, Briganti A, De Visschere P, Fütterer J, Ghadjar P, Giannarini G, Isbarn H, Massard C, Sooriakumaran P, Valerio M, van den Bergh R, Ost P.

Eur Urol Focus. 2016 Dec;2(5):514-521. doi: 10.1016/j.euf.2016.02.009. Epub 2016 Mar 5.

PMID:
28723517
33.

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP.

Eur J Cancer. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12.

PMID:
28618305
34.

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K.

Eur J Cancer. 2017 Aug;81:242. doi: 10.1016/j.ejca.2017.05.003. Epub 2017 Jun 10. No abstract available.

PMID:
28606464
35.

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.

Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Paoletti X, Ribrag V.

Invest New Drugs. 2018 Feb;36(1):62-74. doi: 10.1007/s10637-017-0480-x. Epub 2017 Jun 9.

PMID:
28597151
36.

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.

Matias M, Le Teuff G, Albiges L, Guida A, Brard C, Bacciarelo G, Loriot Y, Massard C, Lassau N, Fizazi K, Escudier B.

Eur J Cancer. 2017 Jul;79:185-192. doi: 10.1016/j.ejca.2017.04.015. Epub 2017 May 13.

PMID:
28511146
37.

Multidisciplinary re-description of Plasmodium (Novyella) paranucleophilum in Brazilian wild birds of the Atlantic Forest kept in captivity.

Tostes R, Dias RJP, Martinele I, Senra MVX, D'Agosto M, Massard CL.

Parasitol Res. 2017 Jul;116(7):1887-1897. doi: 10.1007/s00436-017-5465-3. Epub 2017 May 5.

PMID:
28477100
38.

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.

Cabel L, Loir E, Gravis G, Lavaud P, Massard C, Albiges L, Baciarello G, Loriot Y, Fizazi K.

J Immunother Cancer. 2017 Apr 18;5:31. doi: 10.1186/s40425-017-0232-7. eCollection 2017.

39.

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Aspeslagh S, Shailubhai K, Bahleda R, Gazzah A, Varga A, Hollebecque A, Massard C, Spreafico A, Reni M, Soria JC.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1257-1265. doi: 10.1007/s00280-017-3303-z. Epub 2017 Apr 19.

PMID:
28424962
40.

[Management of a progressing prostate cancer: results of a national study].

Rozet F, Roupret M, Hennequin C, Massard C, Blanchard P, Le Moulec S.

Prog Urol. 2017 May;27(6):381-388. doi: 10.1016/j.purol.2017.02.001. Epub 2017 Apr 6. French.

PMID:
28392429
41.

First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.

Turpin A, Pasquier D, Massard C, Berdah JF, Culine S, Penel N.

Bull Cancer. 2017 Jun;104(6):552-558. doi: 10.1016/j.bulcan.2017.02.002. Epub 2017 Apr 5.

PMID:
28390646
42.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

PMID:
28365644
43.

Otorhinolaryngological Toxicities of New Drugs in Oncology.

Hartl DM, Morel D, Saavedra E, Massard C, Rinaldo A, Saba NF, Ferlito A, Soria JC.

Adv Ther. 2017 Apr;34(4):866-894. doi: 10.1007/s12325-017-0512-0. Epub 2017 Mar 17. Review.

PMID:
28315206
44.

Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157].

Gizzi M, Oberic L, Massard C, Poterie A, Le Teuff G, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K.

Eur J Cancer. 2017 Apr;75:333. doi: 10.1016/j.ejca.2017.02.014. Epub 2017 Mar 7. No abstract available.

PMID:
28283351
45.

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K.

Eur J Cancer. 2017 May;76:36-44. doi: 10.1016/j.ejca.2017.01.024. Epub 2017 Mar 20. Erratum in: Eur J Cancer. 2017 Aug;81:242.

PMID:
28282611
46.

[Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].

Bigot F, Bonnet C, Massard C.

Bull Cancer. 2017 Apr;104(4):370-379. doi: 10.1016/j.bulcan.2017.01.009. Epub 2017 Feb 23. Review. French.

PMID:
28237355
47.

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system.

Benajiba L, Michot JM, Baldini C, Faivre L, Varga A, Balheda R, Gazzah A, Ileana E, Postel-Vinay S, Massard C, de Botton S, Soria JC, Ribrag V.

Anticancer Drugs. 2017 Jun;28(5):540-545. doi: 10.1097/CAD.0000000000000487.

PMID:
28225458
48.

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

Massard C, Mateo J, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J.

Ann Oncol. 2017 Jan 1;28(1):90-95. doi: 10.1093/annonc/mdw441.

49.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, Dieci MV, Kamal M, Diéras V, Gonçalves A, Ferrerro JM, Romieu G, Vanlemmens L, Mouret Reynier MA, Théry JC, Le Du F, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, André F.

PLoS Med. 2016 Dec 27;13(12):e1002201. doi: 10.1371/journal.pmed.1002201. eCollection 2016 Dec.

50.

Hematological changes associated with hemoplasma infection in cats in Rio de Janeiro, Brazil.

Raimundo JM, Guimarães A, Botelho CF, Peixoto MP, Pires MS, Machado CH, Santos HA, Massard CL, André MR, Machado RZ, Baldani CD.

Rev Bras Parasitol Vet. 2016 Oct-Dec;25(4):441-449. doi: 10.1590/S1984-29612016086. Epub 2016 Dec 8.

Supplemental Content

Loading ...
Support Center